



Promotion Gustave Roussy

Portfolio études onco sarcomes - Juin 2021

FaR-RMS

An overarching study for children and adults with
Frontline and Relapse RhabdoMyoSarcoma

Tout patient avec RMS, tout âge, tout stade, diagnostic et rechute

Inclusion objective: 480 patients in France

60 patients in Front line/year

20 patients in R/R/year

Overall, 1260 patients for the whole FaRRMS
(840 front line and 420 relapsed pts)

Promoteur France: Gustave Roussy

PI France: V Minard-Colin – F Duffaud – V Laurence



FaR-RMS is International




Countries
Open
Australia
Denmark
Greece
Israel
Netherlands
Norway
Slovenia
UK

Green = Open Countries

Orange = Countries in Set-up

Red = Potential Countries

FaR-RMS Treatment Questions Open



Open Q3-Q4 2021 : VIT vs VI+rego in Relapse

Etudes ancillaires – France et Europe

Imagerie (Standard of Care)

- FDG-PET Sub Study : diagnosis – C3
- DW-MRI Sub Study

Biologie (AO 2021)

- Structuration Nationale – Centralisation CLB matériel FFPE
- ctDNA
- New Fusions, Xomic,
- Radiosensibilité
- Immune TME/TLS
- Genetic

Long Term Follow-up – Gonado toxicité



Agenda– France

Notes informations patient (n=31) finalisées

Soumission CPP Juill 2021

Questionnaire Faisabilité envoyé 38 centres SFCE/GSF (dont 14 adultes)

RTQA Valérie Bernier

Ouverture Q3-Q4 2021!

